Fluid Motion – Νεα Συνθεση 30 Tablets 1400mg Each
Provides several nutrients for normal cartilage function and for the maintenance of normal connective tissues
Cartilage atrophy is a problem affecting athletes and ordinary people. This alteration often turns into a reduction of the intra-articular space, resulting in joint soreness. This problem is caused by repeated micro traumas occurring during the athletic movement, sometimes worsened by an unfavorable anatomical situation and by a possible non-optimal movement biomechanics. Usually a pain near the rotula appears at rest and on exertion (for example contracting the quadriceps, while walking up and down the stairs) and at pressure. Joint fluidity may be enhanced by using substances (e.g. glucosamine, chondroitin sulfate, galactosamine glucoronoglycan, hyaluronic acid) which contribute to the “reconstruction” of cartilage and may help to contain or reduce the painful syntoms linked to its alteration.
30 Tablets 1400mg Each
Thanks to Vitamin C, Copper and standardised extract of bioactive Curcumin BCM95®, it is useful for normal cartilage function and for the maintenance of normal connective tissues.
It is recommended to take 1 tablet per day.
Glucosamine D-sulfate 2 KCl (from shellfish), bulking agent: cellulose; chondroitinsulfate, zinc gluconate, coated Vitamin C (L-ascorbic acid, stabilizer: ethylcellulose), sodium hyaluronate, bromelain 2500 GDU/g, BCM95® (Curcumin dry extract tit. to 95% in curcuminoids) (Curcuma Longa L., dry extract rhizome) anticaking agents: magnesium salts of fatty acids, silicon dioxide; coating agents: hydroxypropyl methylcellulose, glycerol, hydroxypropyl cellulose, copper gluconate, colouring: titanium dioxide.
Product and brand owned by ES Italia S.r.l.
|Per tablet||%NRV Per tablet|
|Glucosamine D-sulfate||500 mg||–|
|Sodium hyaluronate||35 mg||–|
|Bromelain of which enzymatic activity||30 mg 75 GDU||–|
|BCM95® Curcumin e.s.of which curcuminoids||25 mg 23,75 mg||–|
|Vitamin C||50 mg||63%|
NRV: Nutrient Reference Values (adults) according to Reg. (EU) No 1169/2011